Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Novel hybrid three-dimensional artificial liver using human induced pluripotent stem cells and a rat decellularized liver scaffold.

Minami T, Ishii T, Yasuchika K, Fukumitsu K, Ogiso S, Miyauchi Y, Kojima H, Kawai T, Yamaoka R, Oshima Y, Kawamoto H, Kotaka M, Yasuda K, Osafune K, Uemoto S.

Regen Ther. 2019 Mar 30;10:127-133. doi: 10.1016/j.reth.2019.03.002. eCollection 2019 Jun.

2.

Differentiation and isolation of iPSC-derived remodeling ductal plate-like cells by use of an AQP1-GFP reporter human iPSC line.

Matsui S, Ochiai M, Yasuda K, Mae SI, Kotaka M, Toyoda T, Yamamoto T, Osafune K.

Stem Cell Res. 2019 Mar;35:101400. doi: 10.1016/j.scr.2019.101400. Epub 2019 Jan 31.

3.

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.

Mol Cancer Ther. 2018 Dec;17(12):2788-2795. doi: 10.1158/1535-7163.MCT-18-0694. Epub 2018 Oct 1.

PMID:
30275242
4.

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.

Satake H, Sagawa T, Fujikawa K, Hatachi Y, Yasui H, Kotaka M, Kato T, Tsuji A.

Cancer Chemother Pharmacol. 2018 Nov;82(5):839-845. doi: 10.1007/s00280-018-3678-5. Epub 2018 Aug 30.

5.

A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.

Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K.

Cancer Med. 2018 Sep;7(9):4217-4227. doi: 10.1002/cam4.1623. Epub 2018 Jul 26.

6.

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Jul 6;9(52):30023. doi: 10.18632/oncotarget.25775. eCollection 2018 Jul 6.

7.

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Apr 10;9(27):18811-18820. doi: 10.18632/oncotarget.24702. eCollection 2018 Apr 10. Erratum in: Oncotarget. 2018 Jul 6;9(52):30023. Ichikawa, Wararu [corrected to Ichikawa, Wataru].

8.

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.

Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M.

ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018.

9.

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.

Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16.

PMID:
29555258
10.

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A.

Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9.

11.

Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).

Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).

Oncology. 2018;94(5):289-296. doi: 10.1159/000486624. Epub 2018 Mar 7.

PMID:
29514163
12.

Adrenergic receptor agonists induce the differentiation of pluripotent stem cell-derived hepatoblasts into hepatocyte-like cells.

Kotaka M, Toyoda T, Yasuda K, Kitano Y, Okada C, Ohta A, Watanabe A, Uesugi M, Osafune K.

Sci Rep. 2017 Dec 1;7(1):16734. doi: 10.1038/s41598-017-16858-5.

13.

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.

Sunakawa Y, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Ichikawa W.

Target Oncol. 2017 Dec;12(6):787-794. doi: 10.1007/s11523-017-0527-0.

PMID:
29064002
14.

Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice.

Hitomi H, Kasahara T, Katagiri N, Hoshina A, Mae SI, Kotaka M, Toyohara T, Rahman A, Nakano D, Niwa A, Saito MK, Nakahata T, Nishiyama A, Osafune K.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaaj2300. doi: 10.1126/scitranslmed.aaj2300.

PMID:
28954928
15.

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study.

Satake H, Yasui H, Kotake T, Okita Y, Hatachi Y, Kotaka M, Kato T, Tsuji A.

Mol Clin Oncol. 2017 Sep;7(3):347-350. doi: 10.3892/mco.2017.1335. Epub 2017 Jul 19.

16.

Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).

Satake H, Miki A, Kondo M, Kotake T, Okita Y, Hatachi Y, Yasui H, Imai Y, Ichikawa C, Murotani K, Hashida H, Kobayashi H, Kotaka M, Kato T, Kaihara S, Tsuji A.

ESMO Open. 2017 Mar 9;2(1):e000130. doi: 10.1136/esmoopen-2016-000130. eCollection 2017.

17.

Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.

Satake H, Kondo M, Mizumoto M, Kotake T, Okita Y, Ogata T, Hatachi Y, Yasui H, Miki A, Imai Y, Ichikawa C, Murotani K, Kotaka M, Kato T, Kaihara S, Tsuji A.

Anticancer Res. 2017 Jul;37(7):3703-3710.

PMID:
28668863
18.

Corrigendum to "Modelling urea-cycle disorder citrullinemia type 1 with disease-specific iPSCs" [Biochem. Biophys. Res. Commun. 486(3) (2017) 613-619].

Yoshitoshi-Uebayashi EY, Toyoda T, Yasuda K, Kotaka M, Nomoto K, Okita K, Yasuchika K, Okamoto S, Takubo N, Nishikubo T, Soga T, Uemoto S, Osafune K.

Biochem Biophys Res Commun. 2017 Jul 1;488(3):570-571. doi: 10.1016/j.bbrc.2017.05.055. Epub 2017 May 18. No abstract available.

PMID:
28528898
19.

Modelling urea-cycle disorder citrullinemia type 1 with disease-specific iPSCs.

Yoshitoshi-Uebayashi EY, Toyoda T, Yasuda K, Kotaka M, Nomoto K, Okita K, Yasuchika K, Okamoto S, Takubo N, Nishikubo T, Soga T, Uemoto S, Osafune K.

Biochem Biophys Res Commun. 2017 May 6;486(3):613-619. doi: 10.1016/j.bbrc.2017.03.037. Epub 2017 Mar 14. Erratum in: Biochem Biophys Res Commun. 2017 Jul 1;488(3):570-571.

PMID:
28302489
20.

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.

Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse ME, Ryoo BY, Shen L, Sakamoto J, Kim TW.

Chin J Cancer. 2016 Dec 22;35(1):102. doi: 10.1186/s40880-016-0166-3.

21.

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.

Sunakawa Y, Ichikawa W, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Nakajima T.

Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6.

PMID:
27856123
22.

Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer.

Kotaka M, Ikeda F, Tsujie M, Yoshioka S, Nakamoto Y, Ishii T, Kyogoku T, Kato T, Tsuji A, Kobayashi M.

Onco Targets Ther. 2016 Jul 7;9:4113-20. doi: 10.2147/OTT.S104140. eCollection 2016.

23.

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).

Tsuji A, Sunakawa Y, Ichikawa W, Nakamura M, Kochi M, Denda T, Yamaguchi T, Shimada K, Takagane A, Tani S, Kotaka M, Kuramochi H, Furushima K, Koike J, Yonemura Y, Takeuchi M, Fujii M, Nakajima T.

Target Oncol. 2016 Dec;11(6):799-806.

PMID:
27306648
24.

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ.

Cancer Biol Ther. 2016 Jul 2;17(7):751-9. doi: 10.1080/15384047.2016.1178426. Epub 2016 Apr 22.

25.

Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).

Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, Yoshino T, Ohtsu A, Watanabe T, Matsuda F.

Ann Oncol. 2016 Jun;27(6):1143-8. doi: 10.1093/annonc/mdw074. Epub 2016 Feb 18.

PMID:
27069012
26.

Feasibility of single-incision laparoscopic cholecystectomy for acute cholecystitis.

Ikumoto T, Yamagishi H, Iwatate M, Sano Y, Kotaka M, Imai Y.

World J Gastrointest Endosc. 2015 Dec 25;7(19):1327-33. doi: 10.4253/wjge.v7.i19.1327.

27.

Porcine CD38 exhibits prominent secondary NAD(+) cyclase activity.

Ting KY, Leung CF, Graeff RM, Lee HC, Hao Q, Kotaka M.

Protein Sci. 2016 Mar;25(3):650-61. doi: 10.1002/pro.2859. Epub 2016 Jan 12.

28.

A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.

Yoshida Y, Hirata K, Matsuoka H, Iwamoto S, Kotaka M, Fujita H, Aisu N, Hoshino S, Kosaka T, Maeda K, Kiyomi F, Yamashita Y.

Drug Des Devel Ther. 2015 Nov 11;9:6067-73. doi: 10.2147/DDDT.S94901. eCollection 2015.

29.

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.

Soda H, Maeda H, Hasegawa J, Takahashi T, Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, Oba K, Mishima H.

BMC Cancer. 2015 Oct 14;15:695. doi: 10.1186/s12885-015-1685-z.

30.

Prospective evaluation of the proportion of sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps with hyperplastic features.

Sano W, Sano Y, Iwatate M, Hasuike N, Hattori S, Kosaka H, Ikumoto T, Kotaka M, Fujimori T.

Endosc Int Open. 2015 Aug;3(4):E354-8. doi: 10.1055/s-0034-1391948. Epub 2015 May 5.

31.

The addition of high magnifying endoscopy improves rates of high confidence optical diagnosis of colorectal polyps.

Iwatate M, Sano Y, Hattori S, Sano W, Hasuike N, Ikumoto T, Kotaka M, Murakami Y, Hewett DG, Soetikno R, Kaltenbach T, Fujimori T.

Endosc Int Open. 2015 Apr;3(2):E140-5. doi: 10.1055/s-0034-1391362. Epub 2015 Feb 17.

32.

Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches.

Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M, Okubo C, Nishikawa M, Oishi A, Narita M, Miyashita I, Asano K, Hayashi K, Osafune K, Yamanaka S, Saito H, Yoshida Y.

Cell Stem Cell. 2015 Jun 4;16(6):699-711. doi: 10.1016/j.stem.2015.04.005. Epub 2015 May 21.

33.

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).

Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T.

Cancer Chemother Pharmacol. 2015 Jul;76(1):75-84. doi: 10.1007/s00280-015-2757-0. Epub 2015 May 16.

34.

Narrow-band imaging observation of colorectal lesions using NICE classification to avoid discarding significant lesions.

Hattori S, Iwatate M, Sano W, Hasuike N, Kosaka H, Ikumoto T, Kotaka M, Ichiyanagi A, Ebisutani C, Hisano Y, Fujimori T, Sano Y.

World J Gastrointest Endosc. 2014 Dec 16;6(12):600-5. doi: 10.4253/wjge.v6.i12.600.

35.

Expression, purification, crystallization and preliminary X-ray analysis of full-length human RIG-I.

Kwok J, Hui KP, Lescar J, Kotaka M.

Acta Crystallogr F Struct Biol Commun. 2014 Feb;70(Pt 2):248-51. doi: 10.1107/S2053230X14000430. Epub 2014 Jan 22.

36.

Structural basis for discriminatory recognition of Plasmodium lactate dehydrogenase by a DNA aptamer.

Cheung YW, Kwok J, Law AW, Watt RM, Kotaka M, Tanner JA.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):15967-72. doi: 10.1073/pnas.1309538110. Epub 2013 Sep 16.

37.

Structural basis of FliG-FliM interaction in Helicobacter pylori.

Lam KH, Lam WW, Wong JY, Chan LC, Kotaka M, Ling TK, Jin DY, Ottemann KM, Au SW.

Mol Microbiol. 2013 May;88(4):798-812. doi: 10.1111/mmi.12222. Epub 2013 Apr 24.

38.

Structure of Crimean-Congo hemorrhagic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage.

Wang Y, Dutta S, Karlberg H, Devignot S, Weber F, Hao Q, Tan YJ, Mirazimi A, Kotaka M.

J Virol. 2012 Nov;86(22):12294-303. doi: 10.1128/JVI.01627-12. Epub 2012 Sep 5.

39.

Structural insights into the regulatory mechanism of the response regulator RocR from Pseudomonas aeruginosa in cyclic Di-GMP signaling.

Chen MW, Kotaka M, Vonrhein C, Bricogne G, Rao F, Chuah ML, Svergun D, Schneider G, Liang ZX, Lescar J.

J Bacteriol. 2012 Sep;194(18):4837-46. doi: 10.1128/JB.00560-12. Epub 2012 Jun 29.

40.

Expression, purification, crystallization and preliminary X-ray analysis of Plasmodium falciparum GTP:AMP phosphotransferase.

Law AW, Lescar J, Hao Q, Kotaka M.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Jun 1;68(Pt 6):671-4. doi: 10.1107/S1744309112015862. Epub 2012 May 23.

41.

The variable N-terminal region of DDX5 contains structural elements and auto-inhibits its interaction with NS5B of hepatitis C virus.

Dutta S, Gupta G, Choi YW, Kotaka M, Fielding BC, Song J, Tan YJ.

Biochem J. 2012 Aug 15;446(1):37-46. doi: 10.1042/BJ20120001.

PMID:
22640416
42.

Structural studies of intermediates along the cyclization pathway of Aplysia ADP-ribosyl cyclase.

Kotaka M, Graeff R, Chen Z, Zhang LH, Lee HC, Hao Q.

J Mol Biol. 2012 Jan 20;415(3):514-26. doi: 10.1016/j.jmb.2011.11.022. Epub 2011 Nov 18.

PMID:
22138343
43.

Predictive factors for anastomotic leakage after simultaneous resection of synchronous colorectal liver metastasis.

Nakajima K, Takahashi S, Saito N, Kotaka M, Konishi M, Gotohda N, Kato Y, Kinoshita T.

J Gastrointest Surg. 2012 Apr;16(4):821-7. doi: 10.1007/s11605-011-1782-5. Epub 2011 Nov 29.

44.

Induced-fit upon ligand binding revealed by crystal structures of the hot-dog fold thioesterase in dynemicin biosynthesis.

Liew CW, Sharff A, Kotaka M, Kong R, Sun H, Qureshi I, Bricogne G, Liang ZX, Lescar J.

J Mol Biol. 2010 Nov 26;404(2):291-306. doi: 10.1016/j.jmb.2010.09.041. Epub 2010 Oct 1.

PMID:
20888341
45.

Molecular interaction of flagellar export chaperone FliS and cochaperone HP1076 in Helicobacter pylori.

Lam WW, Woo EJ, Kotaka M, Tam WK, Leung YC, Ling TK, Au SW.

FASEB J. 2010 Oct;24(10):4020-32. doi: 10.1096/fj.10-155242. Epub 2010 Jun 25.

PMID:
20581225
46.

Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications.

Luo D, Wei N, Doan DN, Paradkar PN, Chong Y, Davidson AD, Kotaka M, Lescar J, Vasudevan SG.

J Biol Chem. 2010 Jun 11;285(24):18817-27. doi: 10.1074/jbc.M109.090936. Epub 2010 Apr 7.

47.

Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation.

Min L, Mohammad Isa SA, Shuai W, Piang CB, Nih FW, Kotaka M, Ruedl C.

J Immunol. 2010 May 1;184(9):4625-9. doi: 10.4049/jimmunol.0903873. Epub 2010 Mar 31.

48.

Expression, purification and preliminary crystallographic analysis of Pseudomonas aeruginosa RocR protein.

Kotaka M, Dutta S, Lee HC, Lim MJ, Wong Y, Rao F, Mitchell EP, Liang ZX, Lescar J.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Oct 1;65(Pt 10):1035-8. doi: 10.1107/S1744309109034526. Epub 2009 Sep 25.

49.

Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38.

Graeff R, Liu Q, Kriksunov IA, Kotaka M, Oppenheimer N, Hao Q, Lee HC.

J Biol Chem. 2009 Oct 2;284(40):27629-36. doi: 10.1074/jbc.M109.030965. Epub 2009 Jul 28.

50.

The functional role of a conserved loop in EAL domain-based cyclic di-GMP-specific phosphodiesterase.

Rao F, Qi Y, Chong HS, Kotaka M, Li B, Li J, Lescar J, Tang K, Liang ZX.

J Bacteriol. 2009 Aug;191(15):4722-31. doi: 10.1128/JB.00327-09. Epub 2009 Apr 17.

Supplemental Content

Loading ...
Support Center